Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($)	Common Stock	Additional Paid In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2023	$ 1,663	$ 72,879,738	$ (68,797,872)	$ 4,083,529
Balance (in Shares) at Dec. 31, 2023	1,663,421
Equity-based compensation – stock option expense		177,003		177,003
Exercise of warrants	$ 2,391	3,821,873		3,824,264
Exercise of warrants (in Shares)	2,391,440
Equity-based compensation – stock issuances to consultants and employees		48,987		48,987
Inducement expense		4,464,427		4,464,427
Net loss			(6,476,560)	(6,476,560)
Balance at Mar. 31, 2024	$ 4,054	81,392,028	(75,274,432)	6,121,650
Balance (in Shares) at Mar. 31, 2024	4,054,861
Balance at Dec. 31, 2023	$ 1,663	72,879,738	(68,797,872)	4,083,529
Balance (in Shares) at Dec. 31, 2023	1,663,421
Inducement expense				4,464,427
Net loss				(8,934,858)
Balance at Jun. 30, 2024	$ 4,292	82,005,259	(77,732,730)	4,276,821
Balance (in Shares) at Jun. 30, 2024	4,293,681
Balance at Mar. 31, 2024	$ 4,054	81,392,028	(75,274,432)	6,121,650
Balance (in Shares) at Mar. 31, 2024	4,054,861
Equity-based compensation – stock option expense		153,391		153,391
Sale of common stock, net of transaction costs	$ 238	410,853		411,091
Sale of common stock, net of transaction costs (in Shares)	238,820
Equity-based compensation – stock issuances to consultants and employees		48,987		48,987
Inducement expense
Net loss			(2,458,298)	(2,458,298)
Balance at Jun. 30, 2024	$ 4,292	82,005,259	(77,732,730)	4,276,821
Balance (in Shares) at Jun. 30, 2024	4,293,681
Balance at Dec. 31, 2024	$ 6,473	86,056,934	(81,995,323)	4,068,084
Balance (in Shares) at Dec. 31, 2024	6,474,588
Equity-based compensation – stock option expense		93,301		93,301
Equity-based compensation - stock issuances to a vendor and vesting to employee	$ 100	143,330		143,430
Equity-based compensation - stock issuances to a vendor and vesting to employee (in Shares)	100,000
Net proceeds from sale of common stock	$ 77	50,571		50,648
Net proceeds from sale of common stock (in Shares)	75,000
Net loss			(2,228,801)	(2,228,801)
Balance at Mar. 31, 2025	$ 6,650	86,344,136	(84,224,124)	2,126,662
Balance (in Shares) at Mar. 31, 2025	6,649,588
Balance at Dec. 31, 2024	$ 6,473	86,056,934	(81,995,323)	4,068,084
Balance (in Shares) at Dec. 31, 2024	6,474,588
Inducement expense
Net loss				(4,187,357)
Balance at Jun. 30, 2025	$ 21,535	91,751,821	(86,182,680)	5,590,676
Balance (in Shares) at Jun. 30, 2025	21,534,695
Balance at Mar. 31, 2025	$ 6,650	86,344,136	(84,224,124)	2,126,662
Balance (in Shares) at Mar. 31, 2025	6,649,588
Equity-based compensation – stock option expense		75,099		75,099
Exercise of warrants	$ 9,477	2,212,455		2,221,932
Exercise of warrants (in Shares)	9,477,240
Inducement expense
Equity-based compensation - stock issuances to a vendor and vesting to employee		49,000		49,000
Net proceeds from sale of common stock	$ 5,408	3,071,131		3,076,539
Net proceeds from sale of common stock (in Shares)	5,407,867
Net loss			(1,958,556)	(1,958,556)
Balance at Jun. 30, 2025	$ 21,535	$ 91,751,821	$ (86,182,680)	$ 5,590,676
Balance (in Shares) at Jun. 30, 2025	21,534,695

ADIAL PHARMACEUTICALS, INC. 10-Q